Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor of Matrix Biology Kim Midwood, of the Kennedy Institute of Rheumatology, NDORMS has been named in the BioBeat 2015 Movers and Shakers report.

The 2015 report recognises 50 inspirational women in biobusiness in the UK who are challenging the status quo to bring better health to people around the world. The annual BioBeat report highlights 50 inspirational female entrepreneurs, pioneers and advisors across the industry. 

Founded in 2012 by Miranda Weston-Smith, BioBeat aims to bring fresh energy and growth to the bio sector.  

Successful women entrepreneurs and leaders can support the rapid transformation of the global biobusiness sector, as research suggests they adopt different strategies for success which can lead to business models that more effectively engage talent in broader, more inclusive and more dynamic ways.

Professor Midwood's research focuses on how the cellular microenvironment defines the immune response. She uses a multidisciplinary approach incorporating structural, biochemical, molecular, proteomic and epigenetic tools to find new diagnostics and therapeutics to control inflammation. 

She founded the BioTech company Nascient Ltd in 2012 to develop new drugs for inhibiting chronic inflammation in diseases such as rheumatoid arthritis. She also has a long history of consulting for biotech companies. 

"I am delighted to be listed in the BioBeat report; it's a real honour to be recognised alongside all the women nominated who have had a tremendous impact in the Bio Tech world, and I hope that this report encourages more women to consider taking on a role in the BioBusiness sector", says Professor Midwood.

Visit 50 Movers and Shakers in BioBusiness 2015 for the full list.

Similar stories

Professor Michael Dustin elected to the National Academy of Sciences

Awards

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.

NDORMS researchers awarded for Dupuytren research

Awards

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease

Awards Funding

Oxford University has today been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Awards General

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.

Wellcome funding awarded to Oxford team to support research into heart muscle regeneration

Awards Research

An Oxford team from the Centre for Medicines Development, Department of Physiology Anatomy and Genetics and Radcliffe Department of Medicine led by Professor Jagdeep Nanchahal at the Kennedy Institute has been awarded a Wellcome Innovator Award to develop a first in class therapeutic aimed at regenerating heart muscle after heart attack.